Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pathway Genomics Launches Hereditary Colorectal Cancer Genetic Test

Published: Thursday, February 20, 2014
Last Updated: Wednesday, February 19, 2014
Bookmark and Share
Test uses NGS technology to identify gene alterations or mutations.

Pathway Genomics Corporation has announced the launch of Hereditary Colorectal Cancer DNA InsightSM, the company’s premier hereditary cancer genetic test.

Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

“We are committed to providing valuable tools to help physicians further improve the quality of health care,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer. “Our new hereditary colorectal cancer genetic test is part of this commitment as it empowers physicians by providing useful information about cancer risk.”

The American Cancer Society estimates 140,000 colorectal cancer cases in the U.S. in 2013. Additionally, current research data shows, on average, one in 20 people develop colorectal cancer. People with a first-degree relative with colon cancer can have two to three times the risk of developing the disease.

“Colorectal cancer is the second-leading cause of cancer-related deaths in the United States,” said Linda Wasserman, M.D., Ph.D., Pathway Genomics’ laboratory director and former director of the Clinical Cancer Genetics Care Unit at UC San Diego Moores Cancer Center. “The genetic mutations that we test for can increase a patient’s lifetime risk for the development of colorectal cancer by as much as 50 to 80 percent.”

The Hereditary Colorectal Cancer DNA Insight genetic test scans a patient’s genome for a number of conditions related to colorectal cancer, including Lynch syndrome, familial adenomatous polyposis, Li-Fraumeni syndrome, juvenile polyposis, MUTYH-associated polyposis, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer, and PTEN-hamartoma tumor syndrome. Additionally, many of the genes tested play a role in other cancer types, which will also be reported to the clinician.

As part of its cancer test, Pathway Genomics offers a complimentary Familial Studies Program, which provides genetic testing to family members of qualified patients who are found to have genetic mutations where the risk for cancer is not fully understood - known in the field as a variant of unknown significance (VUS). The test provides information on how the patient and family members may be affected.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Susan G. Komen and Pathway Genomics Sign National Agreement
Agreement to fund community breast cancer education and outreach programs in five cities nationwide.
Wednesday, September 10, 2014
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!